- Home
- ARL vs LRMR Comparison
ARL vs LRMR Comparison
Compare ARL & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARL
- LRMR
- Stock Information
- Founded
- ARL 1999
- LRMR N/A
- Country
- ARL United States
- LRMR United States
- Employees
- ARL N/A
- LRMR N/A
- Industry
- ARL Building operators
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- ARL Real Estate
- LRMR Health Care
- Exchange
- ARL Nasdaq
- LRMR Nasdaq
- Market Cap
- ARL 205.1M
- LRMR 204.9M
- IPO Year
- ARL N/A
- LRMR N/A
- Fundamental
- Price
- ARL $12.70
- LRMR $3.74
- Analyst Decision
- ARL
- LRMR Strong Buy
- Analyst Count
- ARL 0
- LRMR 7
- Target Price
- ARL N/A
- LRMR $17.86
- AVG Volume (30 Days)
- ARL 4.7K
- LRMR 1.5M
- Earning Date
- ARL 08-15-2025
- LRMR 08-11-2025
- Dividend Yield
- ARL N/A
- LRMR N/A
- EPS Growth
- ARL N/A
- LRMR N/A
- EPS
- ARL N/A
- LRMR N/A
- Revenue
- ARL $48,234,000.00
- LRMR N/A
- Revenue This Year
- ARL N/A
- LRMR N/A
- Revenue Next Year
- ARL N/A
- LRMR N/A
- P/E Ratio
- ARL N/A
- LRMR N/A
- Revenue Growth
- ARL N/A
- LRMR N/A
- 52 Week Low
- ARL $9.43
- LRMR $1.61
- 52 Week High
- ARL $19.68
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- ARL 41.78
- LRMR 60.69
- Support Level
- ARL $12.55
- LRMR $3.18
- Resistance Level
- ARL $13.92
- LRMR $3.89
- Average True Range (ATR)
- ARL 0.77
- LRMR 0.32
- MACD
- ARL -0.02
- LRMR -0.03
- Stochastic Oscillator
- ARL 9.68
- LRMR 55.70
About ARL American Realty Investors Inc.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.